Group targets drugs most needing study for off-label use

May 2009
Journal of Business (10756124);5/7/2009, Vol. 24 Issue 10, pB6
Trade Publication
The article focuses on the effort of a group of researchers to develop a list of prescribed medications that need additional study to determine effectivity and safety for their off-label uses. According to the article, the list noted antidepressants and antipsychotics as drugs that have high levels of off-label use without scientific support. Associate professor of medicine Randall Stafford stated that the list might be a start to confront the problem of off-label use with little evidence.


Related Articles

  • Medication Research for Young Children in Community Practice: Retrospect and Prospect. A Commentary. Zito, Julie Magno // Journal of Early Childhood & Infant Psychology;2009, Issue 5, p121 

    In this article the author discusses medication use in very young children. According to the author, pharmacoepidemiology is the study of medication use in large populations, and to apply this pharmacoepidemiology framework to the evaluation of drug use in young children, there is need to expand...

  • Off-Label Antidepressant Use in Children and Adolescents. Czaja, Angela // Pediatrics for Parents;Sep/Oct2013, Vol. 28 Issue 9/10, p27 

    The article presents information on the use of off-label antidepressants in children and adolescents in the U.S. It states that all medicines that physicians prescribe children, must be approved by the U.S. Food and Drug Administration (FDA). FDA approves new medications only after scientific...

  • GSK lawyer is charged with making false statements to FDA. Tanne, Janice Hopkins // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/20/2010, Vol. 341 Issue 7782, p1070 

    The article reports on the charges imposed by the U.S. Department of Justice against Lauren Stevens, a retired lawyer of GlaxoSmithKline (GSK), for the off-label marketing of the antidepressant bupropion. Stevens is facing obstructing an official proceeding, one count of concealing and...

  • When doctors prescribe "off-label".  // Consumer Reports on Health;Dec2009, Vol. 21 Issue 12, p8 

    The article focuses on off-label drugs which sometimes being prescribed by the doctor unknowingly not just for the reasons approved by the U.S. Food and Drug Administration (FDA). It is noted that 25% of the doctors prescribed the antidepressant paroxetine for bipolar disorder where evidence...

  • Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use. Pickar, David; Vinik, Jessie; Bartko, John J. // PLoS ONE;2008, Vol. 3 Issue 9, p1 

    Multiple drug class combinations are often prescribed for the treatment of schizophrenia, although antipsychotic monotherapy reflects FDA labeling and scientific justification for combinations is highly variable. This study was performed to gain current data regarding drug treatment of...

  • Tricyclic antidepressants and headaches: systematic review and meta-analysis. Jackson, Jeffrey L.; Shimeall, William; Sessums, Laura; DeZee, Kent J.; Becher, Dorothy; Diemer, Margretta; Berbano, Elizabeth; O'Malley, Patrick G. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/23/2010, Vol. 341 Issue 7778, p869 

    The article focuses on a study which compared the efficacy of tricyclic antidepressants and selective serotonin reuptake inhibitors in the treatment of migraine, tension headache and mixed headaches. Study authors reviewed 37 randomized trials of adults receiving tricyclics or selective...

  • Changing Rx Practices in the Treatment of Mental Illiness Impact on Foronsic Evidence. Cole, Sherwood // Forensic Examiner;Spring2009, Vol. 18 Issue 1, p14 

    Tha article discusses how off-label prescription practices are useful in the treatment of mental illness and its impact on forensic evidence. The tricyclic antidepressants Desipramine is not only effective in curing adult patients with Attention Deficit Hyperactivity Disorder symptoms. The...

  • Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Dörks, Michael; Langner, Ingo; Dittmann, Ulrich; Timmer, Antje; Garbe, Edeltraut // European Child & Adolescent Psychiatry;Aug2013, Vol. 22 Issue 8, p511 

    The off-label use of drugs in children and adolescents is widespread. In Germany, the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants (OADs) is not licensed for the treatment of depressive disorders in children and adolescents except for fluoxetine, which was...

  • Speak Out. Wright, David; Avallone, Anthony N.; Berger, Aaron; Wrenn, John // Urology Times;4/1/2009, Vol. 37 Issue 4, p30 

    The article presents answers to a question on whether pharmaceutical companies be allowed to market pharmaceutical products for off-label use.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics